) Clinical and laboratory scientists at NYU Medical Center are collaborating to further exploit prior experience and integrate it with the plan of development of phase I anticancer drugs by the National Cancer Institute (NCI). Specifically, we have selected to focus on: 1) The integration of camptothecins into the locoregional approaches to cancer treatment, 2) the pharmacodynamics of modulators and cytoprotective agents alone and in combination with established anticancer drugs such as platinums and topoisomerase II inhibitors, and 3) The Study and development of gene therapy strategies utilizing tumor-targeted vectors bearing suicide genes introduced both locoregionally, and systemically. The resources of the Kaplan Cancer Center are ideally suited for these ambitious projects: a Pharmacology Core Laboratol has extensive experience with obtaining correlative biological endpoints, an Immunohistochemistry Research Laboratory has been thoroughly integrated with recent clinical studies, a protein-DNA cross-linking assay is available to dissect modulation of platinum action. Collaborations are a v a ilable for camptothecin action, gene therapy, pharmacodynamics of radioimmunoconjugates, deoxynucleotide pools in mononuclear gel preparation, in-situ PCR studes of tumor enzymes, and other laboratories with expertise in cytokines, angiogenesis, antimitotics, among other widely explored therapeutic areas. The clinical investigators have the necessary experience, patient resources, and organization to succeed in these endeavors and to cooperate extensively with the NCI and other phase I investigators in the introduction of novel anticancer treatments, and in refining existing successful therapies. Moreover, they have a track record for the eventual transfer of findings on a wide scale locally and nationally.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RLB-7 (O1))
Program Officer
Jensen, Leeann T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York University
Internal Medicine/Medicine
Schools of Medicine
New York
United States
Zip Code
Ott, Patrick A; Hamilton, Anne; Jones, Amanda et al. (2010) A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. PLoS One 5:e8714
Pavlick, Anna C; Wu, Jennifer; Roberts, John et al. (2009) Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. Cancer Chemother Pharmacol 64:803-10
Ramanathan, Ramesh K; Egorin, Merrill J; Takimoto, Chris H M et al. (2008) Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 26:563-9
Hochster, Howard; Chen, Thomas T; Lu, Janice M et al. (2008) Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. Gynecol Oncol 108:500-4
Mani, S; McDaid, H M; Grossman, A et al. (2007) Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone. Ann Oncol 18:190-5
Synold, Timothy W; Takimoto, Chris H; Doroshow, James H et al. (2007) Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 13:3660-6
Takimoto, Chris H; Graham, Martin A; Lockwood, Graham et al. (2007) Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res 13:4832-9
Hochster, Howard S; Plimack, Elizabeth R; Mandeli, John et al. (2006) Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study. Gynecol Oncol 100:324-9
Hulit, James; Lee, Richard J; Li, Zhiping et al. (2006) p27Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling. Cancer Res 66:8529-41
Hamilton, A L; Eder, J P; Pavlick, A C et al. (2005) Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 23:6107-16

Showing the most recent 10 out of 24 publications